NHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)
This funding opportunity invites researchers to utilize existing genetic and multi-omics data to uncover the underlying biological mechanisms of heart, lung, blood, and sleep disorders, with the goal of advancing precision medicine in these areas.
Description
This Funding Opportunity Announcement (FOA) invites applications to use the NHLBI-funded TransOmics for Precision Medicine (TOPMed) program to generate a large volume of integrated genetic and multi-omics data to facilitate discovery of the molecular mechanisms of heart, lung, blood, and sleep (HLBS) disorders. The overall goal is to transition the program from genetic Map to Mechanism (M2) and to fill knowledge gaps that have not been sufficiently covered by existing TOPMed datasets. No funding will be provided under this FOA. The omics and related phenotypic data will be deposited in a public NIH-designated controlled-access database such as the database for Genotypes and Phenotypes (dbGaP) and NHLBIs BioData Catalyst (BDC).